Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05435846 · ClinicalTrials.gov registry record · Phase 1
Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation
A Phase 1 study, sponsored by Collin Blakely.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT05435846 is a Phase 1 study that was terminated before completion, run by Collin Blakely. The registered enrollment target is 3 participants.
The verdict
NCT05435846, a Phase 1 study, was terminated before completion, sponsored by Collin Blakely.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This phase I/Ib trial studies the side effects and best doses of capmatinib plus trametinib when given together for the treatment of patients with MET exon 14 skipping mutation non-small cell lung cancer that has spread to other places in the body (metastatic). Capmatinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Trametinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells. Capmatinib and trametinib are "targeted therapies." These targeted therapies work by detecting and targeting a mutation in the MET gene. Giving Capmatinib and trametinib may kill more tumor cells in patients with metastatic non-small cell lung cancer.
Interventions
- DRUG Capmatinib
- DRUG Trametinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2022-08-10 |
| Est. Completion | 2024-05-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05435846
The ClinicalTrials.gov registry entry for NCT05435846 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Collin Blakely, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Capmatinib is the first listed.
NCT05435846 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05435846 about?
NCT05435846 is a clinical study titled "Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation". This phase I/Ib trial studies the side effects and best doses of capmatinib plus trametinib when given together for the treatment of patients with MET exon 14 skipping mutation non-small cell lung cancer that has spread to other places in the body (metastatic). Capmatinib is in a class of medication...
What is the current status of trial NCT05435846?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2022-08-10. Estimated completion is 2024-05-31.
What interventions are being tested in trial NCT05435846?
The interventions under investigation include: Capmatinib (DRUG), Trametinib (DRUG).
Who is sponsoring clinical trial NCT05435846?
This trial is sponsored by Collin Blakely, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.